Variants in genes like FTO and MC4R influence how your body processes energy and responds to appetite-suppressing signals, potentially affecting fatigue severity
Sanyal will discuss retatrutide and nonalcoholic steatohepatitis (NASH) during Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor TriagonistObesity, NAFLD, and T2D Phase 2 Trial Results on Monday, June 26, at 1:30 p.m
Clinical trials reported mild-to-moderate GI symptoms in 25-50% of patients at 15mg weekly, compared to 15-20% at lower doses
However, real-world clinical trials in humans over 5+ years have not confirmed this risk, and no cases of MTC have been attributed to semaglutide in approved patient populations
A well-known endocrine characteristic of PWS is relative hypoinsulinemia and low insulin resistance, despite severe obesity